Stephen Machatha insider trades: Aldeyra Therapeutics (ALDX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stephen reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | ALDX | ↓ Sell | 22,073 | $5.15 | $114K | Direct | Aug 13, 2025 (2d) |
| Aug 12, 2024 | ALDX | ↓ Sell | 16,041 | $4.74 | $76K | Direct | Aug 14, 2024 (2d) |
| Mar 12, 2024 | ALDX | ↓ Sell | 29,768 | $3.31 | $99K | Direct | Mar 12, 2024 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ALDX insiders
Open-market trades in the last 12 months
About Stephen Machatha's insider trades
Stephen Machatha is Chief Development Officer at Aldeyra Therapeutics (ALDX). Since Mar 12, 2024, Stephen has reported no open-market purchases and 3 sales worth $288K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALDX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.